Polymyositis, an inflammatory disorder of skeletal and occasionally cardiac muscle, may present as a myopathy alone, as one manifestation of a multisystem disorder, especially systemic sclerosis (Medsger, Rodnan, Moossy, and Vester, 1968; Thompson, Bluestone, Bywaters, Dorling, and Johnson, 1969; Brock, 1934) , systemic lupus erythematosus (White, 1959; Dubois, 1966) , and Sjogren's syndrome (Bunim, 1961) , or in association with neoplastic lesions (Williams, 1959; . Weakness, particularly ofthe limb girdle musculature, is the dominant clinical manifestation, pain and tenderness being far less common (Pearson, 1962 (Pearson, , 1966 Shulman, 1969) .
Irrespective of the clinical setting, histologically one finds infiltration of the affected muscle bundles with inflammatory cells, oedema separating myofibrils, and varying degrees of fibrillar fragmentation, degeneration, and regeneration. Loss of muscle mass is the eventual outcome unless effective suppression of the inflammatory process is achieved. Except for the response to surgery in those with resectable malignant lesions, corticosteroids are the drugs of choice (Pearson, 1966 Vignos, Bowling, and Watkins, 1964; Winkelmann, Mulder, Lambert, Howard, and Diessner, 1968) . A significant number of patients, however, resist adequate control with these agents or are unable to tolerate the required dosage level. Improvement in steroid-refractory polymyositis has been reported after addition of the folic acid antagonist, Methotrexate (Malaviya, Many, and Schwartz, 1968; Sokoloff, Goldberg, and Pearson, 1971) . It is our purpose to report five additional patients with steroid-refractory polymyositis treated with Methotrexate, emphasizing the drug toxicity as well as therapeutic response which characterized the majority. From July, 1970 , to December, 1971 , sixteen patients with polymyositis were admitted to the Connective TissueUnit of the Good Samaritan Hospital. The diagnosis of polymyositis was established if, in the absence of a family history of muscle disease, two of the following three criteria were met:
Diagnostic criteria
(1) A history of proximal muscle weakness, confirmed by physical examination; (2) Elevation of one or more muscle enzymes; (3) Muscle biopsy with characteristic histology. In all sixteen patients proximal muscle weakness and elevated muscle enzymes were present. Twelve patients satisfied all three criteria. In three patients (10, 15, and 11) a muscle biopsy was normal despite clinical and chemical evidence of myositis. In one (16) no biopsy was obtained.
Patient classification GROUP I
Six patients (1-6) had polymyositis alone, without skin changes of dermatomyositis, features of other connective tissue diseases, or evidence of malignancy.
GROUP II
In eight patients (7-14), polymyositis was a dominant manifestation of a multisystem connective tissue disorder, most commonly systemic sclerosis (7) (8) (9) (10) (11) (12) . One patient (13) had systemic lupus erythematosus with myositis confined to the pelvic girdle and lower extremities. One (14) had an Methotrexate therapy in polymyositis 537 (bronchial adenoma) in the lung. The latter (16) was of unusual interest in that she evidenced sclerodermatous skin changes over the upper extremities and face, without Raynaud's phenomenon or features other than the myopathy to support a diagnosis of systemic sclerosis.
Selection of patients for Methotrexate
The inflammatory myopathy was managed successfully with corticosteroids in ten (63 per cent.) of the sixteen patients, including the two with neoplasm which was respectable in one (16). One patient (13) March, 1970 , with muscle weakness of 4 months' duration. After the gradual onset of weakness in the lower extremities, he developed weakness in the upper extremities and difficulty swallowing associated with a 50 lb weight loss.
Physical examination
The patient was a well-developed white male who appeared chronically ill. There was marked wasting and weakness in the proximal muscles of the upper and lower extremities without muscle tenderness or pain on stretch. The remainder of the examination was normal except for the stigmata of chronic obstructive pulmonary disease and mild congestive heart failure. February, 1971 , to SGOT 39, CPK 355, aldolase 22-3, Methotrexate was increased to 50 mg. weekly; the enzymes remained elevated but without deterioration in muscle strength.
Laboratory investigations
The patient was again admitted to hospital in April, 1971, with renal colic and Proteus sepsis which responded well to antibiotic therapy. Re-evaluation of the liver function revealed an increase in alkaline phosphatase and 5' nucleotidase. A liver scan revealed diffuse hepatomegaly without focal defects. The patient refused a liver biopsy. Because of possible Methotrexate hepatotoxicity, this drug was discontinued. Prednisone was increased from 15 to 30 mg./day, which proved to be the required maintenance level. Since discontinuing Methotrexate and increasing steroids, however, his muscle strength has progressively deteriorated.
Case 4, a 47-year-old hospital housekeeper, was entirely well until September, 1969, when she noted weakness of the upper extremities and, one week later, difficulty in rising from chairs and climbing stairs. One month later nasal speech developed, and she began to regurgitate liquids through the nose. Muscle andjoint pain on exercise, and a 24-lb weight loss occurred during the 2 months before admission to hospital in November, 1969.
Physical examination
The patient was a chronically ill black female. There was patchy frontal alopecia and hyperpigmentation over the metacarpophalangeal and proximal interphalangeal joints.
There was no sclerodermatous thickening. Musculoskeletal evaluation revealed nasal speech with poor palatal and pharyngeal contractions, marked proximal weakness in the muscles of the neck, shoulder, and pelvic girdles, and tenderness in the deltoids, biceps, and quadriceps muscles. There was tenderness of the first three proximal interphalangeal joints bilaterally and both wrists. Small effusions were present in both knees. The remainder of the examination, including that of the nervous system, gave normal results. In November, 1970, after 11 months of therapy, prednisone was reduced to 25 mg./day, and enzymes began to increase. In February, 1971, the patient again developed aching in the thighs and difficulty in rising from a chair. She was re-admitted to hospital, and on examination, there was marked weakness in the strap muscles of the neck, shoulder abductors, triceps, quadriceps, and psoas without muscle tenderness. The remainder of the physical examination was normal. Muscle enzymes: SGOT 19, SGPT 27, LDH 650, CPK 420, aldolase 8-7.
Methotrexate therapy was initiated with weekly 25 mg. intravenous injections. Prednisone was continued at 25 mg./day. After 3 weeks of Methotrexate therapy, the weakness was minimal, and enzymes SGOT 12, SGPT 1 1, CPK 243, LDH 312, aldolase 6 1. After 5 weeks there was no demonstrable muscle weakness, but the CPK remained elevated at 177 and the LDH at 311. At 11 weeks all muscle enzymes were normal.
The patient was maintained on weekly Methotrexate for 5 months, and then on bi-weekly injections over the next 5 months. At the present time, a maintenance schedule of 25 mg. at 3-week intervals is continued, in conjunction with prednisone, 25 mg./day. Muscle strength has remained normal, and muscle enzymes have also been normal except for the CPK which varies from 60 to 80 units. There has been no clinical or laboratory evidence of drug toxicity.
Case 7, a 19-year-old black college student, began to develop progressive weakness in both arms in March, 1969 . In July, her private physician recorded proximal muscle weakness in both the upper and the lower extremities, muscle enzyme elevation, and a muscle biopsy consistent with active polymyositis. Prednisone 40 mg./day was begun and tapered to 20 mg./day over 5 months. Muscle weakness continued, and she was hospitalized in November, 1969. In addition to moderate proximal weakness, sclerodactyly was present. SGOT 154, CPK 4471, aldolase 22-7. Prednisone 80 mg./day was instituted, and in 5 months all muscle enzymes and muscle strength returned to normal.
In June, 1970, Raynaud's phenomenon and significant hypertension with diastolic pressures of 130-160 mm. Hg developed. In addition to sclerodactyly, the skin over the hands, arms, face and anterior chest was sclerodermatous. Fine crepitant rales were present in both lower lung fields. Muscle strength and other investigations, including muscle enzymes, were normal. A repeat muscle biopsy demonstrated fibrosis between muscle bundles and a few regenerating myofibrils. Pulmonary function studies revealed a reduced vital capacity, Fev1, and CO diffusing capacity. Motility studies demonstrated aperistalsis of the distal two-thirds of the oesophagus and reduced amplitudes of contractions in the upper oesophagus and pharynx. Prednisone was tapered to 45 mg./day, and hypertension was controlled with guanethidine.
By December, 1970, prednisone had been tapered to 20 mg./day. Proximal limb-girdle muscle weakness recurred, and muscle enzymes increased, and the patient was re-admitted in February, 1971, for immunosuppressive therapy.
The patient was markedly Cushingoid. Vital signs including blood pressure were normal. The sclerodermatous skin changes were unchanged. End-inspiratory dry rales were present at both lung bases. The heart was enlarged, with S2P louder than S2A. There was marked proximal muscle weakness in the upper and lower extremities, and bilateral thigh tenderness. The remainder of the examination was normal.
Laboratory investigations
Haematocrit After 4 months muscle strength began to improve, although the enzymes remained elevated: SGOT 28, SGPT 21, LDH 680, CPK 350, aldolase3 9. Thepulmonary findings cleared, but the CO diffusing capacity remained low at 8-4 (37 per cent. predicted). After 5 months, the patient was able to rise from the supine position and from a chair. All enzymes became normal at 9 months, and normal muscle strength was regained at 11 months. Prednisone had been tapered to 20 mg./day. The patient continues to do well on maintenance Methotrexate 25 mg./week and prednisone 20 mg./day. Case 5, a 69-year-old retired manual labourer, had been in excellent health except for a peptic ulcer treated medically in 1962. Approximately 1 year before admission he noted the insidious onset of weakness in the lower extremities. During the 4 months before admission, in April, 1970, a 40 lb weight loss occurred. At no time did he experience muscle pain, dysphagia, skin rash, or Raynaud's phenomenon.
Physical examination
The patient was an obese black man in no distress. There was 1+ bilateral pretibial oedema. Moderate weakness in the quadriceps and iliopsoas was noted bilaterally. Minimal weakness was present in the proximal muscles of the upper extremities and neck. No muscle tenderness was detected. The other results of the examination were within normal limits. On chemical grounds, the Methotrexate-treated patients had more severe disease. The serum level of each of the muscle enzymes were higher in these five patients (Table II) ; furthermore, more uniform elevation of enzymes was found in them than in those with milder disease and varying enzyme patterns (Table III) . As evident in the steroid-treated patients, the SGOT and CPK were most sensitive, each being elevated in 81 per cent. of those tested. Less sensitive were the SGPT (36 per cent.), the LDH (55 per cent.), and the aldolase (50 per cent.). Of interest, but unexplained, was a transient initial rise in aldolase in three of six patients.
Laboratory investigations
Of these patients with more severe and progressive disease, one (3) was steroid-refractory, and three (4, 7, 5) required higher dosage levels of prednisone than could be tolerated. The final patient (6) had fulminant disease which did not permit any therapeutic trial on steroids alone. The response to therapy was determined by two criteria, namely, improvement in muscle strength and return to normal of elevated muscle enzymes (Table IV) . Of the five patients, three improved and one showed no response. The remaining patient was treated concomitantly with high-dose steroids and Methotrexate, and his improvement could be attributed to either or both drugs, since he had previously received steroids only in low dosage with little benefit. Two patients regained normal muscle strength, and significant improvement occurred in two. The muscle enzymes reverted to normal in three patients and were progressively declining in the patient (6) who died. Only one patient (5) demonstrated no significant change, clinically or chemically.
Maximal muscle strength had returned at 5 weeks (after a dosage of 125 mg.) in one, 14 weeks (575 mg.) in another, and 44 weeks (1,060 mg.) in the one patient treated exclusively by the oral route.
Normal enzymes levels occurred as early as 10 weeks and, in the patient on oral therapy as late as 36 weeks. In two patients (3, 7) the chemical response antedated the time of maximal muscle strength; and in the third (4), the reverse was true.
It was necessary to discontinue Methotrexate in three patients because of complications. One patient 544 Annals of the Rheumatic Diseases (3) had achieved maximal benefit and was on maintenance drug when it was stopped at 32 weeks because of hepatotoxicity. Another (5) developed pruritis and refused further therapy after 14 weeks (600 mg.), no benefit having been achieved. In a third patient (6), Methotrexate was discontinued at 10 weeks (360 mg.) in view of probable Methotrexate pneumonitis, although his muscle strength and enzymes had shown marked improvement.
Discussion
Although the aetiology and pathogenesis of polymyositis are still ill-defined, evidence is mounting in support of immunologically-mediated tissue injury. Several investigators have reported observations of altered cell-mediated immunity (Currie, Saunders, Knowles, and Brown, 1971; Saunders, Knowles, and Currie, 1969; Currie, 1970) . More recently, Whitaker and Engel (1972) have emphasized the role of immune-complex deposition by virtue of their demonstration in the vessel walls of skeletal muscle of granular deposits containing immunoglobulins (IgG and IgM) and complement. Clinically, polymyositis is not associated with autoantibodies to nuclear antigens and altered gamma globulin but may also be the dominant manifestation of such immune disorders as systemic lupus erythematosus and Sj 6gren's syndrome.
Thus, there is a reasonable basis for the use of Methotrexate in the significant number of patients (31 per cent our series) who resist adequate control by corticosteroids alone, as it is one of the agents with established immunosuppressive properties (Berlin, Rall, Mead, Freireich, Van Scott, Hertz, and Lipsett, 1963; Rivarola, Friedman and Lawrence, 1967) as well as an anti-inflammatory action (Hersh, Wong, and Freireich, 1966) .
Malaviya and others (1968) first reported the successful treatment of dermatomyositis with Methotrexate alone (one patient) or in combination with corticosteroids (three patients). Dramatic response was noted in each of the four patients within 1 month; and, with continued weekly intravenous therapy, complete remission was achieved in three. Similarly, Sokoloff and others (1971) reported improvement (marked in one, moderate in four) in five ofseven patients. Maximal response was observed between 9 and 19 weeks, after a total dosage of 460 to 825 mg. had been administered intravenously at the rate of 0-8 mg./kg./body weight/week.
As in these previous reports, Methotrexate was found to be therapeutically effective in four of our five patients. The single patient (5) who failed to improve clinically or chemically was otherwise separable from the Methotrexate-responsive group with respect to the prolonged interval (19 months) of active disease before the institution of corticosteroid therapy, as compared to periods of 2 weeks to 6 months in the others.
The time and total dosage required to effect optimal improvement in our patients receiving intravenous therapy was entirely comparable to the course observed by earlier investigators (Malaviya and others, 1968; Sokoloff and others, 1971) . The marked increase in lag time before therapeutic response in the patient (7) necessarily receiving oral Methotrexate (5 mg./day, 5 days/week) is difficult to understand, for patient 4, receiving the same weekly dose of 25 mg. (but intravenously) had achieved normal strength in five weeks and normal enzymes levels in eleven. There does not appear to be a welldefined maximal or minimal dose at which improvement occurs; similarly, toxic manifestations are not dose-related. In contrast to the earlier reports, toxicity was of major concern in our patients. The most frequent was stomatitis, observed in four and most marked and dose-limiting in the two who received oral drug. Chemical hepatitis and pruritis were each observed in one instance. In none was marrow suppression observed. Most serious and also seemingly related to oral administration was probable Methotrexate pneumonitis in two patients, contributing to death in one. There is evidence that oral Methotrexate, administered daily, has greater toxicity than weekly intravenous therapy, probably because of the higher sustained blood levels and less rapid excretion (Mitchell, Wade, DeConti, Bertino, and Calabresi, 1969; Zurek, Ojima, Anderson, Collins, Oberfield, and Sullivan, 1968) .
To date, there are 54 reported cases of Methotrexate lung disease (J. Amer. med. Ass., 1969; Clarysse, Cathey, Cartwright, and Wintrobe, 1969; Schwartz and Kajani, 1969; Pasquinucci, Ferrara, and Castellari, 1971; Robertson, 1970; Filip, Logue, Harle, and Farrar, 1971; Goldman and Moschella, 1971) , all in patients receiving oral or intramuscular therapy; 51 of them had acute lymphocytic leukaemia, in each instance in remission on Methotrexate when the pneumonitic process emerged. The remaining three patients were being treated for dermatological disorders (Filip and others, 1971; Goldman and Moschella, 1971) . Although the Methotrexate lung syndrome was characterized by severe and acute illness with high fever, cough, dyspnoea, hypoxaemia, and pneumonitis, only three (6 per cent) deaths were reported. Response was usually prompt to withdrawal of the drug and, in severe cases, to the institution of corticosteroid therapy as well. In those cases reported earlier, there was no apparent critical dosage level or duration oftherapy related to development of this complication. The radiological picture has been that of a diffuse, bilateral interstitial pneumonitis, more impressive than clinical signs would predict. Three lung biopsies have been re-corded and have demonstrated diffuse lymphocytic infiltration, interstitial and alveolar, with giant cells and non-caseating granulomata.
One, and possibly two, of our patients seemed to show pulmonary toxicity from Methotrexate. In the patient (7) with less certain findings, we were puzzled at the time by the appearance of end-inspiratory crepitant rales bilaterally which would come and go from one day to the next. Although asymptomatic and without associated radiological change, pulmonary function tests did show deterioration with respect to diffusion capacity. Not suspecting Methotrexate toxicity, the drug was continued, and the ausculatory findings disappeared, and pulmonary function improved after corticosteroids were increased. The variability of chest findings initially plus the response to corticosteroids support an inflammatory process as opposed to progression of systemic sclerosis, and a forme fruste of Methotrexate pneumonitis remains highly suspect.
The second patient (6) was in his third week of oral Methotrexate therapy (10th week on the drug) when, first buccal ulceration and then hyperpyrexia and rapidly progressive diffuse pneumonitis appeared. Chest Xrays (Figs la and b) and lung biopsy (Figs 2a and b) were compatible with Methotrexate pneumonitis, although histologically no giant cells or granulomata were found. All bacteriological cultures, including the lung on biopsy, were initially sterile, although virus studies could not be made. Subsequent superinfection and death followed in several weeks despite withdrawal of Methotrexate, massive antibiosis, augmented steroids, and ventilatory assistance.
While the number of patients is small, our experience supports previous reports that Methotrexate may prove efficacious in some patients with polymyositis who cannot be controlled with tolerable levels of steroids alone. However, in contrast to previous authors who consider Methotrexate a relatively safe drug, we find that the toxicity is appreciable and may be severe in those patients who are given the drug by mouth. Certainly, Methotrexate should be reserved for only those individuals with steroid-refractory disease who can be placed on a weekly intravenous regimen under close observation, especially with respect to the pulmonary status.
Summary
Five of sixteen patients with polymyositis, whose disease could not be controlled with corticosteroids alone, received Methotrexate therapy. Four had pure polymyositis while one had myositis associated with systemic sclerosis. As a group, they demonstrated, clinically and chemically, more severe muscle disease than those requiring steroids alone. Three patients clearly responded to the drug, but toxicity was a significant limiting factor. The most serious complication, namely Methotrexate pneumonitis, observed in two patients receiving oral dosage, contributed to death in one. Methotrexate therapy, while a useful adjunct in the steroid-refractory patient, is highly toxic, especially when given orally, and must be used with caution. 
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